• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Entrada Therapeutics, Inc. - Common Stock (NQ:TRDA)

    6.950 +0.050 (+0.72%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 145,255
    Open 6.890
    Bid (Size) 6.940 (3)
    Ask (Size) 6.950 (29)
    Prev. Close 6.900
    Today's Range 6.690 - 7.015
    52wk Range 4.930 - 21.79
    Shares Outstanding 33,197,018
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Entrada Therapeutics to Present at Upcoming Investor Conferences
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -60.2%
    -60.2%
    1 Month
    +19.8%
    +19.8%
    3 Month
    +18.2%
    +18.2%
    6 Month
    -23.2%
    -23.2%
    1 Year
    -59.7%
    -59.7%

    More News

    Read More
    Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock
    Via Benzinga
    Entrada (TRDA) Q2 Revenue Drops 98%
    Via The Motley Fool
    Topics Intellectual Property
    Entrada Therapeutics Inc (NASDAQ:TRDA) Reports Q2 2025 Earnings Miss, Shares Drop in Pre-Market Trading
    Via Chartmill
    Topics Earnings
    Entrada Therapeutics Reports Second Quarter 2025 Financial Results
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Reports First Quarter 2025 Financial Results
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
    Via Benzinga
    Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Reports Third Quarter 2024 Financial Results
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Entrada Therapeutics Reports Second Quarter 2024 Financial Results
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Announces $100 Million Registered Direct Offering
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire
    Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
    From Entrada Therapeutics, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Entrada Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Entrada Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Entrada Therapeutics, Inc. - Common Stock trade on?
    Entrada Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Entrada Therapeutics, Inc. - Common Stock?
    The ticker symbol for Entrada Therapeutics, Inc. - Common Stock is TRDA on the Nasdaq Stock Market
    What is the current price of Entrada Therapeutics, Inc. - Common Stock?
    The current price of Entrada Therapeutics, Inc. - Common Stock is 6.950
    When was Entrada Therapeutics, Inc. - Common Stock last traded?
    The last trade of Entrada Therapeutics, Inc. - Common Stock was at 10/31/25 04:00 PM ET
    What is the market capitalization of Entrada Therapeutics, Inc. - Common Stock?
    The market capitalization of Entrada Therapeutics, Inc. - Common Stock is 230.72M
    How many shares of Entrada Therapeutics, Inc. - Common Stock are outstanding?
    Entrada Therapeutics, Inc. - Common Stock has 231M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.